Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis

Table 4 Rate of safety outcomes in HCV/HIV coinfected patients

Outcomes	Safety		Heterogeneity		Studies
	Total, n/N	Rate%(95%CI)	I²(%)	P
Virological breakthrough	7/741	0.2 (0.0–1.0)	0	0.78	7
Virologica relapse	8/741	0.3 (0.0–1.2)	0	0.72	7
Discontinuation due to AE	2/678	0.0 (0.0–0.1)	0	0.52	6
AEs	301/460	73.9 (38.1–97.6)	98	< 0.01	3
SAEs	16/460	2.7 (0.0–9.5)	85	< 0.01	3

*OBV ombitasvir, PTV paritaprevir, r ritonavir, DSV dasabuvir, RBV ribavirin, CI confidence interval, AEs adverse events, SAEs serious adverse events

ISSN: 1743-422X